Although the use of emapalumab, an anti- IFN-γ monoclonal antibody to treat primary HLH was approved by the FDA in 2018, and several clinical trials showed clinical efficacy without severe side effects, no significant trials support the use of IFN-γ inhibitors in COVID-19 yet (Kim et al., 2021). Here, IFNG is linked to hemophagocytic syndrome.